相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
Gerd R. Burmester et al.
RMD OPEN (2023)
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Linda Stein Gold et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
Laura Pina Vegas et al.
RHEUMATOLOGY (2022)
The risk of COVID-19 in patients with psoriasis: A retrospective cohort study
Jashin J. Wu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Psoriasis: Comorbidities
Fumikazu Yamazaki
JOURNAL OF DERMATOLOGY (2021)
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Increased Cardiovascular Risk and All-cause Death in Patients with Behcet Disease: A Korean Nationwide Population-based Dynamic Cohort Study
Hyo-Suk Ahn et al.
JOURNAL OF RHEUMATOLOGY (2020)
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Abby S. Van Voorhees et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database
C. Vasilakis-Scaramozza et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database
Rebecca Persson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Peter Nash et al.
RHEUMATOLOGY AND THERAPY (2020)
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study
Philip J. Mease et al.
ACR OPEN RHEUMATOLOGY (2020)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research
Andreas Kerschbaumer et al.
RMD OPEN (2020)
Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis
Erica D. Dommasch et al.
JAMA DERMATOLOGY (2019)
Trial of Apremilast for Oral Ulcers in Behcet's Syndrome
Guelen Hatemi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Behcet syndrome: a contemporary view (vol 14, pg 107, 2018)
Hasan Yazici et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
Alvin F. Wells et al.
RHEUMATOLOGY (2018)
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2017)
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Psoriatic Arthritis
Christopher T. Ritchlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Incidence and predictors for cardiovascular events in patients with psoriatic arthritis
Lihi Eder et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J. Edwards et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo et al.
JOURNAL OF RHEUMATOLOGY (2016)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Recognizing and managing comorbidities in psoriatic arthritis
Alexis Ogdie et al.
CURRENT OPINION IN RHEUMATOLOGY (2015)
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Arthur Kavanaugh et al.
JOURNAL OF RHEUMATOLOGY (2015)
Apremilast for Behcet's Syndrome - A Phase 2, Placebo-Controlled Study
Gulen Hatemi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
Peter Schafer
BIOCHEMICAL PHARMACOLOGY (2012)
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Kim Papp et al.
LANCET (2012)
分享论文
